Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinz Drexel

Showing results (11-20 of 278) with videos related to

Pageof 28
Sort By:
Vascular Pharmacology|May 25, 2013
Is type 2 diabetes really a coronary heart disease risk equivalent?Christoph H Saely, Heinz Drexel
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
[Lipid therapy in patients with diabetes]Christoph H Saely, Heinz Drexel
Vascular Pharmacology|October 18, 2016
Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-reviewChristoph H Saely, Heinz Drexel
The New England Journal of Medicine|May 29, 2004
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantationGuenter Hoefle, Hannes Holzmueller, Heinz Drexel
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 12, 2005
Bisphosphonates routine in prevention of post-transplant osteoporosis?Günter Höfle, Hannes Holzmüller, Heinz Drexel
Cardiology|August 12, 2025
Clinical science at the intersection of cardiovascular, metabolic and renal diseases: new approachesHeinz Drexel, Andreas Festa, Dan Atar
Vascular Pharmacology|September 18, 2012
Phytochemicals and their impact on adipose tissue inflammation and diabetesAndreas Leiherer, Axel Mündlein, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy|May 2, 2024
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?Yihong Sun, Koji Hasegawa, Heinz Drexel
The New England Journal of Medicine|August 13, 2010
Combination lipid therapy in type 2 diabetesChristoph H Saely, Philipp Rein, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy|January 7, 2023
Fibrates: one more lost paradise in lipid treatmentHeinz Drexel, Christoph H Saely, Stefan Agewall
Pageof 28

Showing results (11-20 of 278) with videos related to

Sort By:
Pageof 28
Vascular Pharmacology|May 25, 2013
Is type 2 diabetes really a coronary heart disease risk equivalent?Christoph H Saely, Heinz Drexel
Wiener Medizinische Wochenschrift (1946)|March 16, 2010
[Lipid therapy in patients with diabetes]Christoph H Saely, Heinz Drexel
Vascular Pharmacology|October 18, 2016
Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-reviewChristoph H Saely, Heinz Drexel
The New England Journal of Medicine|May 29, 2004
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantationGuenter Hoefle, Hannes Holzmueller, Heinz Drexel
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 12, 2005
Bisphosphonates routine in prevention of post-transplant osteoporosis?Günter Höfle, Hannes Holzmüller, Heinz Drexel
Cardiology|August 12, 2025
Clinical science at the intersection of cardiovascular, metabolic and renal diseases: new approachesHeinz Drexel, Andreas Festa, Dan Atar
Vascular Pharmacology|September 18, 2012
Phytochemicals and their impact on adipose tissue inflammation and diabetesAndreas Leiherer, Axel Mündlein, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy|May 2, 2024
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?Yihong Sun, Koji Hasegawa, Heinz Drexel
The New England Journal of Medicine|August 13, 2010
Combination lipid therapy in type 2 diabetesChristoph H Saely, Philipp Rein, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy|January 7, 2023
Fibrates: one more lost paradise in lipid treatmentHeinz Drexel, Christoph H Saely, Stefan Agewall
Pageof 28